Skip to main content
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE — Investor Relations & Filings

Ticker · VRDN ISIN · US60463E1038 LEI · 549300C775BNYF550E70 US Professional, scientific and technical activities
Open in API
Filings indexed 768 across all filing types
Latest filing 2026-06-03 Declaration of Voting R…
Country US United States of America
Listing US VRDN

About Viridian Therapeutics, Inc.\DE

https://www.viridiantherapeutics.com/

Viridian Therapeutics is a biopharmaceutical company that discovers, develops, and commercializes treatments for patients with serious and rare autoimmune diseases. The company leverages its expertise in antibody discovery and engineering to create optimized therapeutics. Its clinical pipeline is primarily focused on programs for Thyroid Eye Disease (TED) and includes a portfolio of neonatal Fc receptor (FcRn) inhibitors for a range of autoimmune conditions.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a Form 8-K filing, specifically Item 5.07 “Submission of Matters to a Vote of Security Holders,” which provides detailed vote counts on director elections and advisory proposals at the Annual Meeting. This corresponds to an official announcement of shareholder voting results. Therefore, it should be classified as Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-03 English
8-K
Capital/Financing Update Classification · 93% confidence The document is a Form 8-K current report (Item 1.02) detailing a voluntary prepayment and termination of the Company’s Loan and Security Agreement – a clear capital/financing activity and change to the company’s debt structure. This aligns with our “Capital/Financing Update” category.
2026-05-28 English
8-K
Regulatory Filings Classification · 15% confidence The document is an SEC Form 8-K “Current Report” disclosing entry into a material definitive agreement with a contract manufacturer. It does not contain financial statements or earnings, nor is it a proxy, dividend notice, or capital raising announcement. It is a general regulatory announcement filed under the Securities Exchange Act. Therefore, it falls under the fallback category “Regulatory Filings.”
2026-05-26 English
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K “Current Report” announcing the completion of a public equity offering and a convertible senior notes offering, detailing the terms of the indenture, interest, conversion, redemption and repurchase rights. This is a clear disclosure of new financing transactions and capital structure changes rather than an annual or interim financial report, management discussion, or other category. It is best classified as a Capital/Financing Update.
2026-05-11 English
FWP - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
Capital/Financing Update Classification · 94% confidence The document is an Issuer Free Writing Prospectus (Rule 433) announcing the pricing and terms of upsized underwritten public offerings of convertible notes and common stock, detailing amount, pricing, conversion terms, use of proceeds, and underwriters. This is clearly a financing/capital raising update, fitting the “Capital/Financing Update” category.
2026-05-07 English
FWP - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
Regulatory Filings
2026-05-07 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.